beta

APLS

Apellis Pharmaceuticals Inc.

Apls

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

11-13-2018 07-31-2018 04-30-2018 03-19-2018
Actual EPS -0.64 -0.61 -0.43 -0.6
Consensus EPS -0.63 -0.41 -0.27 -0.27
Estimated EPS -0.63 -0.41 -0.27 -0.27
Number of Estimates 1 1 1 1
EPS Surprise -$0.01 -$0.20 -$0.16 -$0.33

Stats

Summary

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of novel therapeutic compounds for autoimmune and inflammatory diseases.

Market Cap: 871 Million

Primary Exchange: Nasdaq Global Select

Website: http://www.apellis.com

Shares Outstanding: 50.3 Million

Float: 48.1 Million

Dividend: 0.0 (0.0%)

Beta: 0.0

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 1.19 Million

Ethical Flags

Animal testing

Longest drawdown: 349 trading days

From: 2018-04-16 To: 2018-12-14

Lowest Point:

Apellis Pharma up 16% on positive APL-2 data

via: SeekingAlpha at 2018-12-03 14:02:14:000

Thinly traded Apellis Pharmaceuticals ( APLS +16.4% ) is up on more than 30% higher volume, albeit on turnover of only 343K shares, on the heels of its announcement of new data from its open-label Phase 2 PLAUDIT study evaluating complement C3 inhibitor APL-2 in patients with autoimmun… read more...

Apellis Pharma up 16% on positive APL-2 data

via: SeekingAlpha at 2018-12-03 14:02:14:000

Thinly traded Apellis Pharmaceuticals ( APLS +16.4% ) is up on more than 30% higher volume, albeit on turnover of only 343K shares, on the heels of its announcement of new data from its open-label Phase 2 PLAUDIT study evaluating complement C3 inhibitor APL-2 in patients with autoimmun… read more...

Apellis Pharma up 16% on positive APL-2 data

via: SeekingAlpha at 2018-12-03 14:02:14:000

Thinly traded Apellis Pharmaceuticals ( APLS +16.4% ) is up on more than 30% higher volume, albeit on turnover of only 343K shares, on the heels of its announcement of new data from its open-label Phase 2 PLAUDIT study evaluating complement C3 inhibitor APL-2 in patients with autoimmun… read more...

Apellis Pharma up 16% on positive APL-2 data

via: SeekingAlpha at 2018-12-03 14:02:14:000

Thinly traded Apellis Pharmaceuticals ( APLS +16.4% ) is up on more than 30% higher volume, albeit on turnover of only 343K shares, on the heels of its announcement of new data from its open-label Phase 2 PLAUDIT study evaluating complement C3 inhibitor APL-2 in patients with autoimmun… read more...

Apellis Pharma up 16% on positive APL-2 data

via: SeekingAlpha at 2018-12-03 14:02:14:000

Thinly traded Apellis Pharmaceuticals ( APLS +16.4% ) is up on more than 30% higher volume, albeit on turnover of only 343K shares, on the heels of its announcement of new data from its open-label Phase 2 PLAUDIT study evaluating complement C3 inhibitor APL-2 in patients with autoimmun… read more...

Apellis Pharma up 16% on positive APL-2 data

via: SeekingAlpha at 2018-12-03 14:02:14:000

Thinly traded Apellis Pharmaceuticals ( APLS +16.4% ) is up on more than 30% higher volume, albeit on turnover of only 343K shares, on the heels of its announcement of new data from its open-label Phase 2 PLAUDIT study evaluating complement C3 inhibitor APL-2 in patients with autoimmun… read more...

Apellis Pharma up 16% on positive APL-2 data

via: SeekingAlpha at 2018-12-03 14:02:14:000

Thinly traded Apellis Pharmaceuticals ( APLS +16.4% ) is up on more than 30% higher volume, albeit on turnover of only 343K shares, on the heels of its announcement of new data from its open-label Phase 2 PLAUDIT study evaluating complement C3 inhibitor APL-2 in patients with autoimmun… read more...

Apellis Pharma up 16% on positive APL-2 data

via: SeekingAlpha at 2018-12-03 14:02:14:000

Thinly traded Apellis Pharmaceuticals ( APLS +16.4% ) is up on more than 30% higher volume, albeit on turnover of only 343K shares, on the heels of its announcement of new data from its open-label Phase 2 PLAUDIT study evaluating complement C3 inhibitor APL-2 in patients with autoimmun… read more...

Apellis Pharma up 16% on positive APL-2 data

via: SeekingAlpha at 2018-12-03 14:02:14:000

Thinly traded Apellis Pharmaceuticals ( APLS +16.4% ) is up on more than 30% higher volume, albeit on turnover of only 343K shares, on the heels of its announcement of new data from its open-label Phase 2 PLAUDIT study evaluating complement C3 inhibitor APL-2 in patients with autoimmun… read more...

Apellis Pharma up 16% on positive APL-2 data

via: SeekingAlpha at 2018-12-03 14:02:14:000

Thinly traded Apellis Pharmaceuticals ( APLS +16.4% ) is up on more than 30% higher volume, albeit on turnover of only 343K shares, on the heels of its announcement of new data from its open-label Phase 2 PLAUDIT study evaluating complement C3 inhibitor APL-2 in patients with autoimmun… read more...

Apellis Pharma up 16% on positive APL-2 data

via: SeekingAlpha at 2018-12-03 14:02:14:000

Thinly traded Apellis Pharmaceuticals ( APLS +16.4% ) is up on more than 30% higher volume, albeit on turnover of only 343K shares, on the heels of its announcement of new data from its open-label Phase 2 PLAUDIT study evaluating complement C3 inhibitor APL-2 in patients with autoimmun… read more...

Apellis Pharma up 16% on positive APL-2 data

via: SeekingAlpha at 2018-12-03 14:02:14:000

Thinly traded Apellis Pharmaceuticals ( APLS +16.4% ) is up on more than 30% higher volume, albeit on turnover of only 343K shares, on the heels of its announcement of new data from its open-label Phase 2 PLAUDIT study evaluating complement C3 inhibitor APL-2 in patients with autoimmun… read more...

Apellis Pharma up 16% on positive APL-2 data

via: SeekingAlpha at 2018-12-03 14:02:14:000

Thinly traded Apellis Pharmaceuticals ( APLS +16.4% ) is up on more than 30% higher volume, albeit on turnover of only 343K shares, on the heels of its announcement of new data from its open-label Phase 2 PLAUDIT study evaluating complement C3 inhibitor APL-2 in patients with autoimmun… read more...

Apellis Pharma up 16% on positive APL-2 data

via: SeekingAlpha at 2018-12-03 14:02:14:000

Thinly traded Apellis Pharmaceuticals ( APLS +16.4% ) is up on more than 30% higher volume, albeit on turnover of only 343K shares, on the heels of its announcement of new data from its open-label Phase 2 PLAUDIT study evaluating complement C3 inhibitor APL-2 in patients with autoimmun… read more...

Midday Gainers / Losers (10/18/2018)

via: SeekingAlpha at 2018-10-18 12:46:41:000

Gainers: PTI +312% . CCCL +136% . ECYT +51% . CNET +29% . CREG +27% . IFMK +24% . ORPN +24% . DXF +20% . ATAI +17% . YECO +20% . More news on: Proteostasis Therapeutics, China Ceramics Co., Ltd., Endocyte, Inc., Stocks on the move, , Top stock market news, … read more...

Midday Gainers / Losers (10/18/2018)

via: SeekingAlpha at 2018-10-18 12:46:41:000

Gainers: PTI +312% . CCCL +136% . ECYT +51% . CNET +29% . CREG +27% . IFMK +24% . ORPN +24% . DXF +20% . ATAI +17% . YECO +20% . More news on: Proteostasis Therapeutics, China Ceramics Co., Ltd., Endocyte, Inc., Stocks on the move, , Top stock market news, … read more...

Midday Gainers / Losers (10/18/2018)

via: SeekingAlpha at 2018-10-18 12:46:41:000

Gainers: PTI +312% . CCCL +136% . ECYT +51% . CNET +29% . CREG +27% . IFMK +24% . ORPN +24% . DXF +20% . ATAI +17% . YECO +20% . More news on: Proteostasis Therapeutics, China Ceramics Co., Ltd., Endocyte, Inc., Stocks on the move, , Top stock market news, … read more...

Apellis Pharma down 17% on hiccup in late-stage study of APL-2

via: SeekingAlpha at 2018-10-18 10:59:55:000

Thinly traded Apellis Pharmaceuticals ( APLS -16.9% ) is down on almost double normal volume, albeit on turnover of only 434K shares, in reaction to its disclosure that it has paused dosing in its Phase 3 clinical trial, OAKS, evaluating APL-2 in patients with geographic atrophy due to ins… read more...

Apellis Pharma down 17% on hiccup in late-stage study of APL-2

via: SeekingAlpha at 2018-10-18 10:59:55:000

Thinly traded Apellis Pharmaceuticals ( APLS -16.9% ) is down on almost double normal volume, albeit on turnover of only 434K shares, in reaction to its disclosure that it has paused dosing in its Phase 3 clinical trial, OAKS, evaluating APL-2 in patients with geographic atrophy due to ins… read more...

Apellis Pharma down 17% on hiccup in late-stage study of APL-2

via: SeekingAlpha at 2018-10-18 10:59:55:000

Thinly traded Apellis Pharmaceuticals ( APLS -16.9% ) is down on almost double normal volume, albeit on turnover of only 434K shares, in reaction to its disclosure that it has paused dosing in its Phase 3 clinical trial, OAKS, evaluating APL-2 in patients with geographic atrophy due to ins… read more...

Ra Pharma's zilucoplan shows favorable PK profile in renal impairment patients, expanding potential clinical programs

via: SeekingAlpha at 2018-09-26 08:14:53:000

Results from a Phase 1b assessing the pharmacokinetics of Ra Pharmaceuticals' (NASDAQ: RARX ) RA101495 SC (zilucoplan) in patients with severe renal impairment showed a similar profile compared to healthy patients. There were no adverse events reported and the data indicate that no adjust… read more...

Ra Pharma's zilucoplan shows favorable PK profile in renal impairment patients, expanding potential clinical programs

via: SeekingAlpha at 2018-09-26 08:14:53:000

Results from a Phase 1b assessing the pharmacokinetics of Ra Pharmaceuticals' (NASDAQ: RARX ) RA101495 SC (zilucoplan) in patients with severe renal impairment showed a similar profile compared to healthy patients. There were no adverse events reported and the data indicate that no adjust… read more...

Ra Pharma's zilucoplan shows favorable PK profile in renal impairment patients, expanding potential clinical programs

via: SeekingAlpha at 2018-09-26 08:14:53:000

Results from a Phase 1b assessing the pharmacokinetics of Ra Pharmaceuticals' (NASDAQ: RARX ) RA101495 SC (zilucoplan) in patients with severe renal impairment showed a similar profile compared to healthy patients. There were no adverse events reported and the data indicate that no adjust… read more...

Daily Insider Ratings Round Up 9/24/18

via: SeekingAlpha at 2018-09-25 16:24:10:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 9/19/18

via: SeekingAlpha at 2018-09-21 16:12:12:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 9/19/18

via: SeekingAlpha at 2018-09-21 16:12:12:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 9/19/18

via: SeekingAlpha at 2018-09-21 16:12:12:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 9/19/18

via: SeekingAlpha at 2018-09-21 16:12:12:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Dosing underway in Apellis Pharma's late-stage program of APL-2 in geographic atrophy

via: SeekingAlpha at 2018-09-12 08:00:05:000

The first participant has been dosed in a Phase 3 clinical trial, OAKS , evaluating Apellis Pharmaceuticals' (NASDAQ: APLS ) APL-2 in patients with geographic atrophy (GA) (advanced age-related macular degeneration), a condition affecting ~1M Americans. More news on: Apellis Pharmaceuti… read more...

Dosing underway in Apellis Pharma's late-stage program of APL-2 in geographic atrophy

via: SeekingAlpha at 2018-09-12 08:00:05:000

The first participant has been dosed in a Phase 3 clinical trial, OAKS , evaluating Apellis Pharmaceuticals' (NASDAQ: APLS ) APL-2 in patients with geographic atrophy (GA) (advanced age-related macular degeneration), a condition affecting ~1M Americans. More news on: Apellis Pharmaceuti… read more...

Dosing underway in Apellis Pharma's late-stage program of APL-2 in geographic atrophy

via: SeekingAlpha at 2018-09-12 08:00:05:000

The first participant has been dosed in a Phase 3 clinical trial, OAKS , evaluating Apellis Pharmaceuticals' (NASDAQ: APLS ) APL-2 in patients with geographic atrophy (GA) (advanced age-related macular degeneration), a condition affecting ~1M Americans. More news on: Apellis Pharmaceuti… read more...

Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication

via: SeekingAlpha at 2018-09-07 16:31:01:000

News in focus: REPH, MNKD Recro Pharma plans to resubmit NDA Discussion : On September 4, Recro Pharma ( REPH ) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the comp… read more...

Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication

via: SeekingAlpha at 2018-09-07 16:31:01:000

News in focus: REPH, MNKD Recro Pharma plans to resubmit NDA Discussion : On September 4, Recro Pharma ( REPH ) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the comp… read more...

Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication

via: SeekingAlpha at 2018-09-07 16:31:01:000

News in focus: REPH, MNKD Recro Pharma plans to resubmit NDA Discussion : On September 4, Recro Pharma ( REPH ) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the comp… read more...

Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication

via: SeekingAlpha at 2018-09-07 16:31:01:000

News in focus: REPH, MNKD Recro Pharma plans to resubmit NDA Discussion : On September 4, Recro Pharma ( REPH ) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the comp… read more...

Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication

via: SeekingAlpha at 2018-09-07 16:31:01:000

News in focus: REPH, MNKD Recro Pharma plans to resubmit NDA Discussion : On September 4, Recro Pharma ( REPH ) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the comp… read more...

Apellis Pharma up 3% on encouraging APL-2 data

via: SeekingAlpha at 2018-09-04 13:53:17:000

Apellis Pharmaceuticals ( APLS +2.5% ) is up on below-average volume on the heels of its update on a Phase 1b clinical trial, PHAROAH , evaluating APL-2 in patients with paroxysmal nocturnal hemoglobinuria (PNH) on Alexion Pharmaceuticals' ( ALXN -2.5% ) Soliris (eculizumab) who are sev… read more...

Apellis Pharma up 3% on encouraging APL-2 data

via: SeekingAlpha at 2018-09-04 13:53:17:000

Apellis Pharmaceuticals ( APLS +2.5% ) is up on below-average volume on the heels of its update on a Phase 1b clinical trial, PHAROAH , evaluating APL-2 in patients with paroxysmal nocturnal hemoglobinuria (PNH) on Alexion Pharmaceuticals' ( ALXN -2.5% ) Soliris (eculizumab) who are sev… read more...

Apellis Pharma up 3% on encouraging APL-2 data

via: SeekingAlpha at 2018-09-04 13:53:17:000

Apellis Pharmaceuticals ( APLS +2.5% ) is up on below-average volume on the heels of its update on a Phase 1b clinical trial, PHAROAH , evaluating APL-2 in patients with paroxysmal nocturnal hemoglobinuria (PNH) on Alexion Pharmaceuticals' ( ALXN -2.5% ) Soliris (eculizumab) who are sev… read more...

Rigel Pharmaceuticals: A Look At The Competition

via: SeekingAlpha at 2018-08-28 11:00:09:000

In April the FDA approved Rigel Pharmaceuticals ( RIGL ) fostamatinib (Tavalisse) for chronic immune thrombocytopenic purpura (ITP). I had predicted approval but found myself noting the potential for a sell off soon after. Following approval of Tavalisse, it seemed likely the market&#x2019… read more...

Rigel Pharmaceuticals: A Look At The Competition

via: SeekingAlpha at 2018-08-28 11:00:09:000

In April the FDA approved Rigel Pharmaceuticals ( RIGL ) fostamatinib (Tavalisse) for chronic immune thrombocytopenic purpura (ITP). I had predicted approval but found myself noting the potential for a sell off soon after. Following approval of Tavalisse, it seemed likely the market&#x2019… read more...

Rigel Pharmaceuticals: A Look At The Competition

via: SeekingAlpha at 2018-08-28 11:00:09:000

In April the FDA approved Rigel Pharmaceuticals ( RIGL ) fostamatinib (Tavalisse) for chronic immune thrombocytopenic purpura (ITP). I had predicted approval but found myself noting the potential for a sell off soon after. Following approval of Tavalisse, it seemed likely the market&#x2019… read more...

Apellis Pharmaceuticals reports Q2 results

via: SeekingAlpha at 2018-07-31 16:47:31:000

Apellis Pharmaceuticals (NASDAQ: APLS ): Q2 EPS of -$1.44 More news on: Apellis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Apellis Pharmaceuticals reports Q2 results

via: SeekingAlpha at 2018-07-31 16:47:31:000

Apellis Pharmaceuticals (NASDAQ: APLS ): Q2 EPS of -$1.44 More news on: Apellis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Apellis Pharmaceuticals reports Q2 results

via: SeekingAlpha at 2018-07-31 16:47:31:000

Apellis Pharmaceuticals (NASDAQ: APLS ): Q2 EPS of -$1.44 More news on: Apellis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-07-30 08:28:52:000

ADMA Biologics (NASDAQ: ADMA ) initiated with Buy rating and $10 (64% upside) price target at Chardan. More news on: ADMA Biologics Inc, Galapagos, Apellis Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

3 Things In Biotech, July 25: A Chinese Blitz Continues

via: SeekingAlpha at 2018-07-25 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. BeiGene launches two big studies Company: BeiGene ( BGNE ) and Celgene ( CELG ) Thera… read more...

3 Things In Biotech, July 25: A Chinese Blitz Continues

via: SeekingAlpha at 2018-07-25 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. BeiGene launches two big studies Company: BeiGene ( BGNE ) and Celgene ( CELG ) Thera… read more...

3 Things In Biotech, July 25: A Chinese Blitz Continues

via: SeekingAlpha at 2018-07-25 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. BeiGene launches two big studies Company: BeiGene ( BGNE ) and Celgene ( CELG ) Thera… read more...

Apellis Pharma's APL-2 Fast Track'd for GA

via: SeekingAlpha at 2018-07-24 10:07:41:000

The FDA designates Apellis Pharmaceuticals' ( APLS -0.4% ) APL-2, a complement factor C3 inhibitor, for Fast Track review for the treatment of patients with an advanced form of age-related macular degeneration called geographic atrophy (GA). More news on: Apellis Pharmaceuticals, Inc… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-07-10 08:15:22:000

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated withy Outperform rating and $40 (97% upside) price target at Cowen and Company. More news on: Apellis Pharmaceuticals, Inc., Krystal Biotech, Rocket Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-07-10 08:15:22:000

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated withy Outperform rating and $40 (97% upside) price target at Cowen and Company. More news on: Apellis Pharmaceuticals, Inc., Krystal Biotech, Rocket Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-07-10 08:15:22:000

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated withy Outperform rating and $40 (97% upside) price target at Cowen and Company. More news on: Apellis Pharmaceuticals, Inc., Krystal Biotech, Rocket Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Apellis Pharmaceuticals (APLS) Investor Presentation - Slideshow

via: SeekingAlpha at 2018-06-27 14:40:47:000

The following slide deck was published by Apellis Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Apellis Pharmaceuticals (APLS) Investor Presentation - Slideshow

via: SeekingAlpha at 2018-06-27 14:40:47:000

The following slide deck was published by Apellis Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Apellis Pharmaceuticals (APLS) Investor Presentation - Slideshow

via: SeekingAlpha at 2018-06-27 14:40:47:000

The following slide deck was published by Apellis Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Institutional Top Ideas: Cormorant Asset Management

via: SeekingAlpha at 2018-06-16 18:41:14:000

In the last entry of this series we took a look at top ideas from EcoR1 Capital, a hedge fund with high returns and a higher percentage of the portfolio in its top 10 holdings (making it a good one to keep tabs on). The series is down to its last two funds to be reviewed, as usual trying t… read more...

Institutional Top Ideas: Cormorant Asset Management

via: SeekingAlpha at 2018-06-16 18:41:14:000

In the last entry of this series we took a look at top ideas from EcoR1 Capital, a hedge fund with high returns and a higher percentage of the portfolio in its top 10 holdings (making it a good one to keep tabs on). The series is down to its last two funds to be reviewed, as usual trying t… read more...

Institutional Top Ideas: Cormorant Asset Management

via: SeekingAlpha at 2018-06-16 18:41:14:000

In the last entry of this series we took a look at top ideas from EcoR1 Capital, a hedge fund with high returns and a higher percentage of the portfolio in its top 10 holdings (making it a good one to keep tabs on). The series is down to its last two funds to be reviewed, as usual trying t… read more...

Institutional Top Ideas: Cormorant Asset Management

via: SeekingAlpha at 2018-06-16 18:41:14:000

In the last entry of this series we took a look at top ideas from EcoR1 Capital, a hedge fund with high returns and a higher percentage of the portfolio in its top 10 holdings (making it a good one to keep tabs on). The series is down to its last two funds to be reviewed, as usual trying t… read more...

Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)

via: SeekingAlpha at 2018-05-31 09:04:00:000

This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXNs competition. I have previously reviewed a large number of ALXNs compet… read more...

Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)

via: SeekingAlpha at 2018-05-31 09:04:00:000

This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXNs competition. I have previously reviewed a large number of ALXNs compet… read more...

Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)

via: SeekingAlpha at 2018-05-31 09:04:00:000

This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXNs competition. I have previously reviewed a large number of ALXNs compet… read more...

Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)

via: SeekingAlpha at 2018-05-31 09:04:00:000

This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXNs competition. I have previously reviewed a large number of ALXNs compet… read more...

Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)

via: SeekingAlpha at 2018-05-31 09:04:00:000

This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXNs competition. I have previously reviewed a large number of ALXNs compet… read more...

Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)

via: SeekingAlpha at 2018-05-31 09:04:00:000

This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXNs competition. I have previously reviewed a large number of ALXNs compet… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-24 08:40:34:000

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Overweight rating and $52 (164% upside) price target at Cantor Fitzgerald. Shares up 9% premarket. More news on: Apellis Pharmaceuticals, Inc., Marinus Pharmaceuticals, uniQure N.V., Healthcare stocks news, Stocks on the mo… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-24 08:40:34:000

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Overweight rating and $52 (164% upside) price target at Cantor Fitzgerald. Shares up 9% premarket. More news on: Apellis Pharmaceuticals, Inc., Marinus Pharmaceuticals, uniQure N.V., Healthcare stocks news, Stocks on the mo… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-24 08:40:34:000

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Overweight rating and $52 (164% upside) price target at Cantor Fitzgerald. Shares up 9% premarket. More news on: Apellis Pharmaceuticals, Inc., Marinus Pharmaceuticals, uniQure N.V., Healthcare stocks news, Stocks on the mo… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-24 08:40:34:000

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Overweight rating and $52 (164% upside) price target at Cantor Fitzgerald. Shares up 9% premarket. More news on: Apellis Pharmaceuticals, Inc., Marinus Pharmaceuticals, uniQure N.V., Healthcare stocks news, Stocks on the mo… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-24 08:40:34:000

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Overweight rating and $52 (164% upside) price target at Cantor Fitzgerald. Shares up 9% premarket. More news on: Apellis Pharmaceuticals, Inc., Marinus Pharmaceuticals, uniQure N.V., Healthcare stocks news, Stocks on the mo… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-24 08:40:34:000

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Overweight rating and $52 (164% upside) price target at Cantor Fitzgerald. Shares up 9% premarket. More news on: Apellis Pharmaceuticals, Inc., Marinus Pharmaceuticals, uniQure N.V., Healthcare stocks news, Stocks on the mo… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-24 08:40:34:000

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Overweight rating and $52 (164% upside) price target at Cantor Fitzgerald. Shares up 9% premarket. More news on: Apellis Pharmaceuticals, Inc., Marinus Pharmaceuticals, uniQure N.V., Healthcare stocks news, Stocks on the mo… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-24 08:40:34:000

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Overweight rating and $52 (164% upside) price target at Cantor Fitzgerald. Shares up 9% premarket. More news on: Apellis Pharmaceuticals, Inc., Marinus Pharmaceuticals, uniQure N.V., Healthcare stocks news, Stocks on the mo… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-24 08:40:34:000

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Overweight rating and $52 (164% upside) price target at Cantor Fitzgerald. Shares up 9% premarket. More news on: Apellis Pharmaceuticals, Inc., Marinus Pharmaceuticals, uniQure N.V., Healthcare stocks news, Stocks on the mo… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-24 08:40:34:000

Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Overweight rating and $52 (164% upside) price target at Cantor Fitzgerald. Shares up 9% premarket. More news on: Apellis Pharmaceuticals, Inc., Marinus Pharmaceuticals, uniQure N.V., Healthcare stocks news, Stocks on the mo… read more...

Institutional Top Ideas Series: Ra Capital Management

via: SeekingAlpha at 2018-05-10 02:04:51:000

In the last entry of this series we took a look at top ideas from Orbimed Advisors, a large fund in the midst of a leadership transition which avoids outsized bets (over 5% weighting) yet still has posted decent returns. Going forward, I hope to continue to delve into the portfolios of su… read more...

Institutional Top Ideas Series: Ra Capital Management

via: SeekingAlpha at 2018-05-10 02:04:51:000

In the last entry of this series we took a look at top ideas from Orbimed Advisors, a large fund in the midst of a leadership transition which avoids outsized bets (over 5% weighting) yet still has posted decent returns. Going forward, I hope to continue to delve into the portfolios of su… read more...

Bright Lights On Capitalist Woodstock, Tech Developers And Sports Betting

via: SeekingAlpha at 2018-05-05 08:33:06:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Macro matters: Traders are back to focusing on economic reports after no major deve… read more...

Bright Lights On Capitalist Woodstock, Tech Developers And Sports Betting

via: SeekingAlpha at 2018-05-05 08:33:06:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Macro matters: Traders are back to focusing on economic reports after no major deve… read more...

Apellis Pharmaceuticals beats by $0.88

via: SeekingAlpha at 2018-04-30 17:01:45:000

Apellis Pharmaceuticals (NASDAQ: APLS ): Q1 EPS of -$0.43 beats by $0.88 . Cash and cash equivalents of $152.93M Press Release More news on: Apellis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, read more...

Apellis Pharmaceuticals beats by $0.88

via: SeekingAlpha at 2018-04-30 17:01:45:000

Apellis Pharmaceuticals (NASDAQ: APLS ): Q1 EPS of -$0.43 beats by $0.88 . Cash and cash equivalents of $152.93M Press Release More news on: Apellis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, read more...

Alexion Clears A Path For 2nd Generation PNH Drug

via: SeekingAlpha at 2018-04-30 04:36:41:000

Recently, Alexion Pharmaceuticals ( ALXN ) announced positive results from another phase 3 study for its second generation version of Soliris, known as ALXN1210. This study is good news for the company, because the trial showed that patients can be switched from soliris to ALXN1210 witho… read more...

Alexion Clears A Path For 2nd Generation PNH Drug

via: SeekingAlpha at 2018-04-30 04:36:41:000

Recently, Alexion Pharmaceuticals ( ALXN ) announced positive results from another phase 3 study for its second generation version of Soliris, known as ALXN1210. This study is good news for the company, because the trial showed that patients can be switched from soliris to ALXN1210 witho… read more...

Midday Gainers / Losers (04/17/2018)

via: SeekingAlpha at 2018-04-17 12:40:54:000

Gainers: CNET +42% . WMLP +21% . CIFS +21% . CLXT +20% . IIN +19% . NVLN +15% . IFON +15% . DPW +14% . CHEK +14% . GTHX +14% . More news on: ChinaNet Online Holdings, Inc., Westmoreland Resource Partners, LP, China Internet Nationwide Financial Services Inc… read more...

Midday Gainers / Losers (04/17/2018)

via: SeekingAlpha at 2018-04-17 12:40:54:000

Gainers: CNET +42% . WMLP +21% . CIFS +21% . CLXT +20% . IIN +19% . NVLN +15% . IFON +15% . DPW +14% . CHEK +14% . GTHX +14% . More news on: ChinaNet Online Holdings, Inc., Westmoreland Resource Partners, LP, China Internet Nationwide Financial Services Inc… read more...

Midday Gainers / Losers (04/16/2018)

via: SeekingAlpha at 2018-04-16 12:40:56:000

Gainers: OSN +26% . ERI +17% . SHOS +13% . APLS +13% . HEAR +13% . FTD +12% . FSCT +12% . OASM +11% . PMTS +11% . BXC +11% . More news on: Ossen Innovation Co., Ltd., Eldorado Resorts, Inc., Sears Hometown and Outlet Stores, Inc., Stocks on the move, , … read more...

Midday Gainers / Losers (04/16/2018)

via: SeekingAlpha at 2018-04-16 12:40:56:000

Gainers: OSN +26% . ERI +17% . SHOS +13% . APLS +13% . HEAR +13% . FTD +12% . FSCT +12% . OASM +11% . PMTS +11% . BXC +11% . More news on: Ossen Innovation Co., Ltd., Eldorado Resorts, Inc., Sears Hometown and Outlet Stores, Inc., Stocks on the move, , … read more...

Alexion Spruces Up Its Pipeline With $855 Million Buy Of Rare Disease Drug Maker

via: SeekingAlpha at 2018-04-13 01:45:09:000

Recently, Alexion Therapeutics ( ALXN ) announced that it had acquired Wilson Therapeutics in an all cash deal. The reason for performing the deal was so that Alexion could get another rare disease drug into its pipeline. I believe that this is a good step in the right direction, because the… read more...

Alexion Spruces Up Its Pipeline With $855 Million Buy Of Rare Disease Drug Maker

via: SeekingAlpha at 2018-04-13 01:45:09:000

Recently, Alexion Therapeutics ( ALXN ) announced that it had acquired Wilson Therapeutics in an all cash deal. The reason for performing the deal was so that Alexion could get another rare disease drug into its pipeline. I believe that this is a good step in the right direction, because the… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-04-12 08:46:57:000

Leap Therapeutics (NASDAQ: LPTX ) initiated with Buy rating and $12.50 (29% upside) price target at H.C. Wainwright. Shares up 3% premarket. More news on: Leap Therapeutics, Mallinckrodt PLC, MEI Pharma, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-04-12 08:46:57:000

Leap Therapeutics (NASDAQ: LPTX ) initiated with Buy rating and $12.50 (29% upside) price target at H.C. Wainwright. Shares up 3% premarket. More news on: Leap Therapeutics, Mallinckrodt PLC, MEI Pharma, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Achillion, Omeros, Ra Rx, Reata, Chemocentryx And Others In The IgA Nephropathy Space

via: SeekingAlpha at 2018-04-09 13:39:22:000

I began this article with the intent of an Achillion Pharmaceuticals ( ACHN ) focus. However, as I learned more about each of these 5 companies, I've decided to give an equal spotlight to each. I will preface the real reason for this renal-focused article is due to my own diagnosis of IgA neph… read more...

Achillion, Omeros, Ra Rx, Reata, Chemocentryx And Others In The IgA Nephropathy Space

via: SeekingAlpha at 2018-04-09 13:39:22:000

I began this article with the intent of an Achillion Pharmaceuticals ( ACHN ) focus. However, as I learned more about each of these 5 companies, I've decided to give an equal spotlight to each. I will preface the real reason for this renal-focused article is due to my own diagnosis of IgA neph… read more...

Apellis Pharmaceuticals reports Q4 results

via: SeekingAlpha at 2018-03-19 16:38:11:000

Apellis Pharmaceuticals (NASDAQ: APLS ): Q4 EPS of -$0.79 Cash and equivalents of $175.6M Press Release More news on: Apellis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, read more...

APLS - Addendum, How A Company Tries To Make Lemonade Out Of Lemons

via: SeekingAlpha at 2018-01-14 09:10:11:000

This is just a quick extension to my previous APLS note . I found it remarkable that at the big JP Morgan healthcare conference, the company has made a notable pivot. As I argue that giving an elderly patient with a slowly progressive disease (geographic atrophy) an additional drug-induc… read more...

Apellis On The Decline From Highs Is An Opportunity With Considerable Risks

via: SeekingAlpha at 2018-01-12 12:24:17:000

A quick note before we begin: I collaborate with Avisol Capital Partners and their valuable marketplace service, Total Pharma Tracker . If you were a subscriber, you would have seen this article in advance as an incentive. In the hunt for "sure thing" biotech plays, there is no end to op… read more...

Achillion Pharmaceuticals: Ultra-Rare Disease Company With Ultra-Rare Enterprise Value

via: SeekingAlpha at 2018-01-09 11:31:28:000

Background of the Company Achillion ( ACHN ) is a biopharmaceutical company specializing in discovering and developing small molecules for complement-mediated diseases. The complement system is a part of the human innate immune system and is believed to comprise three pathways - the alt… read more...

Apellis Pharmaceuticals: This Horse Is Lame

via: SeekingAlpha at 2018-01-09 09:38:15:000

The approval of any drug by the FDA is based on the concept of benefit/risk. Obviously, for a drug to get approved, those knowledgeable in the field must believe that the benefits of the drug outweigh the risks. This benefit/risk ratio is a moving target. The risk that a patient would find acc… read more...

Akari's Coversin successful in mid-stage PNH study

via: SeekingAlpha at 2017-12-08 16:39:08:000

A Phase 2 clinical trial, COBALT , assessing Akari Therapeutics' (NASDAQ: AKTX ) lead candidate Coversin in patients with paroxysmal nocturnal hemoglobinuria (PNH) met the primary endpoint of a statistically significant reduction in LDH (lactate dehydrogenase) to within 1.8x the upper lim… read more...

Epidarex Capital Portfolio Company Harpoon Medical Acquired By Edwards Lifesciences

via: PR Newswire at 2017-12-07 06:00:00:000

BETHESDA, Md. , Dec. 7, 2017 /PRNewswire/ --Epidarex Capital ("Epidarex"), an early-stage, transatlantic life science venture fund, today announced that its portfolio company, Harpoon Medical, Inc. ("Harpoon"), a pioneer in beating-heart repair for degenerative mitral regurgit… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2017-12-04 08:42:38:000

ObsEva (NASDAQ: OBSV ) initiated with Outperform rating and $20 (97% upside) price target by BMO Capital Capital Markets. More news on: ObsEva, iRhythm Technologies, InflaRx, Healthcare stocks news, Read more … read more...

Stocks to watch next week

via: SeekingAlpha at 2017-12-02 09:59:00:000

Coming soon: Subscribe to Stocks to Watch every week in article format. Check this space next week for details More news on: Quanterix Corp., Odonate Therapeutics, Curo Group, Consumer stocks news, Tech stocks news, Financial stocks news, Healthcare stocks news, News on ETFs, Read m… read more...

Daily Insider Ratings Round Up 11/13/17: ADMA, S

via: SeekingAlpha at 2017-11-15 12:45:34:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "… read more...

U.S. IPO Weekly Recap: 10 Companies Go Public In The Busiest Week Of 2017

via: SeekingAlpha at 2017-11-14 06:02:24:000

Ten companies raised a combined $1.6 billion in the most active week of the 2017 IPO market. Texas community bank CBTX took the top spot with a 10% pop, which is still below the long-term historical average of 13%. The week featured three regional banks, three biotechs, three fast-growing Ch… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX